Civil society organizations are urging the health ministry to eliminate animal studies in biosimilar development to lower production costs and expedite the process. They emphasize that removing these tests will enhance affordability and uphold ethical standards. The government is revising biosimilar regulations, potentially restricting animal use and prioritizing in-vitro studies, aligning with global standards to ensure safety and efficacy.